The Reisfeld Laboratory

Publications

Publications (selected from 408):

2011 | 2010 | 2009 | 2002 | 2001 | 2000 | 1999 | 1998

2011

Liao, D., Liu, Z., Wrasidlo, W., Chen, T., Luo, YP., Xiang, R. and Reisfeld, R.A. A synthetic enzyme inhibitor is a novel targeting ligand for nanotherapeutic drug delivery inhibiting primary tumor growth without systemic toxicity. Nanomedicine, in press, 2011.

Xiang, R., Liao, D., Cheng, T., Zhou, H., Shi, Q., Chuang, TS, Markowitz, D., Reisfeld, R.A. and Luo, YP. Downregulation of transcription factor SOX2 in cancer stem cells suppresses growth and metastatis of lung cancer. Brit. J. Cancer, 104:1410-1417, 2011.

2010

Luo, Y., Zhou, H., Krueger, J., Kaplan, C., Liao, D., Markowitz, D., Liu, C., Chuang, TS., Xiang, R and Reisfeld, R.A. The Role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression. Oncogene, 4:29(5):662-73, 2010.

2009

Liao, D., Luo, Y., Markowitz, D., Xiang, R. and Reisfeld, R.A. Cancer associated fibroblasts promote tumor growth and metastasis by modulation of the tumor microenvironment in the 4T1 murine breast cancer model. PLoS One, Nov 23:4(11):e7965, 2009.

2002

Niethammer, A.G., Xiang, R., Becker, J.C., Wodrich, H., Pertl, U., Karsten, G., Eliceiri, B.P., and Reisfeld, R.A. A DNA vaccine against vascular endothelial growth factor receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nature Med., In press, December, 2002.

Pertl, U., Wodrich, H., Ruehlmann, J.M., Gillies, S.D., Lode, H.N., and Reisfeld, R. A post-transcriptionally modified DNA-vaccine induces complete protection against metastatic neuroblastoma. Blood, In press, 2002.

Dummer, W., Niethammer, A.G., Baccala, R., Lawson, B.R., Wagner, N., Reisfeld, R.A., and Theofilopoulos, A.N. T cell homeostatic proliferation elicits effective anti-tumor autoimmunity. J. of Clin. Invest., 110:185-192, 2002. Commentary, 110:157-159, 2002.

Hood, J.D., Bednarski, M., Frausto, R., Guccione, S., Reisfeld, R.A., Xiang, R., and Cheresh, D.A. Tumor regression by targeted gene delivery to the neovasculature. Science, 296:2404-2407, 2002.

2001

Ruehlmann, J.M., Xiang, R., Niethammer, A.G., Ba, Y., Pertl, U., Dolman, C.S., Gillies, S.D. and Reisfeld, R.A. MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma. Cancer Res., 61:8498-8503, 2001.

Niethammer, A.G., Primus, F.J., Xiang, R., Dolman, C.S., Ruehlmann, J.M., Gillies, S.D., and Reisfeld, R.A. An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice. Vaccine, 20:421-429, 2001.

Xiang, R., Primus, J.F., Ruehlmann, J.M., Niethammer, A.G., Silletti, S., Lode, H.N., Dolman, C.S., Gillies, S.D., Reisfeld, R.A. A Dual-Function DNA vaccine encoding CEA and CD40 ligand trimer induces protective immunity against colon cancer in CEA-Transgenic mice. J. Immunol., 167:4560-4565, 2001.

Niethammer, A.G., Xiang, R., Ruehlmann, J.M., Lode, H.N., Gillies, S.D. and Reisfeld, R.A. Targeted interleukin-2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma. Cancer Res., 61:6178-6184, 2001.

Pertl, U., Luster, A.D., Varki, N.M., Homann, D., Gaedicke, G., Reisfeld, R.A. and Lode, H.N. IFN-g-Inducible Protein-10 Is Essential for the Generation of a Protective Tumor-Specific CD8 T Cell Response Induced by Single-Chain IL-12 Gene Therapy. J. Immunol., 166:6944-6951, 2001.

Lode, H.N., Pertl, U., Xiang, R., Gaedicke, G. and Reisfeld, R.A. Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma. Med Ped Oncol., 35:641-646, 2000.

Straten, P.T., Guldberg, P., Schrama, D. Moerch, U., Seremet, T., Siedel, C., Reisfeld, R.A. and Becker, J. In situ cytokine therapy: Redistribution of clonally expanded T cell clones. Eur. J. Immunol. 31:250-258, 2001.

Schrama, D., Straten, P.T., Fischer, W.H., McLellan, A.D., Br�cker, E.-B., Reisfeld, R.A. and Becker, J.C. Targeting of lymphotoxin-a to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue. Immunity, 14:111-121, 2001.

Xiang, R., Silletti, S., Lode, H.N., Dolman, C.S., Ruehlmann, J.M., Niethammer, A.G., Pertl, U., Gillies, S.D., Primus, F.J. and Reisfeld. R.A. Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice. Clin. Cancer Res., 7:856s-864s, 2001.

2000

Lode, H.N. and Reisfeld, R.A. Targeted cytokines for cancer immunotherapy. Immunol. Res. 21/2-3:279-288, 2000.

Lode, H.N., Xiang, R., Pertl, U., F�rster, E., Schoenberger, S.P., Gillies, S.D. and Reisfeld, R.A. Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD40L interaction. J. Clin. Invest. 105:1623-1630, 2000.

Xiang, R., Lode, H.N., Chao, T.-H., Ruehlmann, J.M., Dolman, C.S., Rodriguez, F., Whitton, J.L., Overwijk, W.W., Restifo, N.P. and Reisfeld, R.A. An autologous oral DNA vaccine protects against murine melanoma. Proc. Natl. Acad. Sci. USA 97(10):5492-5497, 2000.

Lode, H.N., Xiang, R., Gillies, S.D. and Reisfeld, R.A. Amplification of T cell-mediated immune responses by antibody-cytokine fusion proteins. Immunol. Invest. 29(2):117-120, 2000.

Lode, H.N., Xiang, R., Perri, P., Pertl, U., Lode, A., Gillies, S.D. and Reisfeld, R.A. What to do with targeted IL2. Drugs of Today, in press, 2000.

Lode, H.N. and Reisfeld, R.A. Targeted cytokines for cancer immunotherapy. Immunol. Res., in press, 2000.

Lode, H.N., R. Xiang, Pertl, U., Förster, E., Schoenberger, S.P., Gillies, S.D. and Reisfeld, R.A. Melanoma immunotherapy by targeted IL-2 depends on CD4+ T-cell help mediated by CD40/CD40L interaction. J. Clin. Invest., in press, 2000.

Foon, K.A., Lutzky, J., Baral, R.N., Yannelli, J.R., Hutchins, L., Teitelbaum, A., Kashala, O.L., Das, R., Garrison, J., Reisfeld, R.A. and Bhattacharya-Chatterjee, M. Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J. Clin. Oncol.18:376-384, 2000.

1999

Batova, A., Kamps, A., Gillies, S.D., Reisfeld, R.A. and Yu, A.L. The ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro. Clin. Cancer Res. 5:4259-4263, 1999.

Xiang, R., Lode, H.N., Gillies, S.D. and Reisfeld, R.A. T cell memory against colon carcinoma is long-lived in the absence of antigen. J. Immunol. 163:3676-3683, 1999.

Lode, H.N., Xiang, R., Duncan, S.R., Theofilopoulos, A.N., Gillies, S.D. and Reisfeld, R.A. Tumor-targeted IL2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL12. Proc. Natl. Acad. Sci. USA 96:8591-8596, 1999.

Becker, J.C., Lode, H.N., Straten, P.T. and Reisfeld, R.A. Targeted interleukin-2 therapy for melanoma by immunocytokines. Dermatol. Therapy 10:53-61, 1999.

Pertl, U., Xiang, R., Kleindienst, P., Becker, J.C., Gillies, S.D., Reisfeld, R.A. and Lode, H.N. Tumor targeting with immunocytokines: A novel approach for cancer therapy. Min. Biotech. 10(3):89-99, 1999.

Lode, H.N., Moehler, T., Xiang, R., Gillies, S.D., Cheresh, D.A. and Reisfeld, R.A. Synergy between an anti-angiogenic integrin av antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases. Proc. Natl. Acad. Sci. USA 96:1591-1596, 1999.

1998

Lode, H.N., Xiang, R., Becker, J.C., Gillies, S.D. and Reisfeld, R.A. Immunocytokines: A promising approach to cancer immunotheray. Pharmacol. Ther. 80(3):277-292, 1998.

Sen, G., Chakraborty, M., Foon, K.A., Reisfeld, R.A. and Bhattacharya-Chatterjee, M. Induction of IgG antibodies by an anti-idiotype antibody mimicking disialoganglioside GD2. J. Immunotherapy 21(1):75-83, 1998.

Dolman, C.S., Mueller, B.M., Lode, H.N., Xiang, R., Gillies, S.D. and Reisfeld, R.A. Suppression of human prostate carcinoma metastases in SCID mice by IL2 immunocytokine therapy. Clin. Can. Res. 4:2551-2557, 1998.

Lode, H.N. and Reisfeld, R.A. Immunocytokines for cancer immunotherapy. In "Biomedical Progress," (Mammen, E.F., Ed.), Die Medizinische Verlagsgesellschaft mbH, Marburg, Germany, 11:33-37, 1998.

Xiang, R., Lode, H.N., Dreier, T., Gillies, S.D. and Reisfeld, R.A. Induction of persistent tumor-protective immunity in mice cured of established colon carcinoma metastases. Cancer Res. 58:3918-3925, 1998.

Straten, P.T., Guldberg, P., Seremet, T., Reisfeld, R.A., Zeuthen, J. and Becker, J.C. Activation of preexisting T cell clones by targeted interleukin 2 therapy. Proc. Natl. Acad. Sci. USA 95:8785-8790, 1998.

Dreier, T., Lode, H.N., Xiang, R., Dolman, C.S., Reisfeld, R.A. and Kang, A.S. Recombinant immunocytokines targeting the mouse transferrin receptor: Construction and biological activities. Bioconj. Chem. 9(4):482-489, 1998.

Lode, H.N., Reisfeld, R.A., Handgretinger, R., Nicolaou, K.C., Gaedicke, G. and Wrasidlo, W. Targeted therapy with a novel enediyene antibiotic calicheamicin q I1 effectively suppresses growth and dissemination of liver metastases in a syngeneic model of murine neuroblastoma. Cancer Res. 58:2925-2928, 1998.

Gillies, S.D., Lan, Y., Wesolowski, J.S., Qian, X., Reisfeld, R.A., Holden, S., Super, M. and Lo, K.-M. Antibody-IL12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases. J. Immunol. 160(12):6195-6203, 1998.

Yu, A.L., Uttenreuther-Fischer, M.M., Huang, C.-S., Tsui, C.C., Gillies, S.D., Reisfeld, R.A. and Kung, F.H. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J. Clin. Oncol. 16(6):2169-2180, 1998.

Foon, K.A., Sen, G., Hutchins, L., Kashala, O.L., Baral, R., Banerjee, M., Chakraborty, M., Garrison, J., Reisfeld, R.A. and Bhattacharya-Chatterjee, M. Antibody responses in melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. Clin. Cancer Res. 4:1117-1124, 1998.

Lode, H.N., Xiang, R., Dreier, T., Varki, N.M., Gillies, S.D. and Reisfeld, R.A. Natural killer cell-mediated eradication of neuroblastoma metastases to bone marrow by targeted interleukin-2 therapy. Blood 91(5):1706-1715, 1998.

Lode, H.N., Dreier, T., Xiang, R., Varki, N.M., Kang, A.S. and Reisfeld, R.A. Gene therapy with a single chain interleukin-12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc. Natl. Acad. Sci. USA 95:2475-2480, 1998.

1997

Pancook, J.D., Reisfeld, R.A., Varki, N., Vitiello, A., Fox, R.I. and Montgomery, A.M.P. Expression and regulation of the neural cell adhesion molecule L1 on human cells of myelomonocytic and lymphoid origin. J. Immunol. 158:4413-4421, 1997.

Frost, J.D., Hank, J.A., Reaman, G.H., Frierdick, S., Seeger, R.C., Gan, J., Anderson, P.M., Ettinger, L.J., Cairo, M.S., Blazar, B.R., Krailo, M.D., Matthay, K.K., Reisfeld, R.A. and Sondel, P.M. A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma. Cancer 80(2):317-333, 1997.

Albertini, M.R., Hank, J.A., Schiller, J.H., Khorsand, M., Borchert, A.A., Gan, J., Bechhofer, R., Storer, B., Reisfeld, R.A. and Sondel, P.M. Phase IB trial of chimeric antidisialoganglioside antibody plus interleukin 2 for melanoma patients. Clin. Cancer Res. 3:1277-1288, 1997.

Sen, G., Chakraborty, M., Foon, K.A., Reisfeld, R.A. and Bhattacharya-Chatterjee, M. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2. Clin. Cancer Res. 3:1969-1976, 1997.

Lode, H.N., Xiang, R., Varki, N.M., Dolman, C.S., Gillies, S.D. and Reisfeld, R.A. Targeted interleukin-2 therapy of spontaneous neuroblastoma metastases to bone marrow. J. Natl. Cancer Inst. 89(21):1586-1594, 1997.

Xiang, R., Lode, H.N., Dolman, C.S., Dreier, T., Varki, N.M., Qian, X., Lo, K.-M., Lan, Y., Super, M., Gillies, S.D. and Reisfeld, R.A. Elimination of established murine colon carcinoma metastases by antibody-interleukin 2 fusion protein therapy. Cancer Res. 57:4948-4955, 1997.

Reisfeld, R.A., Becker, J.C. and Gillies, S.D. Immunocytokines: A new approach to immunotherapy of melanoma. Melanoma Res. 7 (suppl 2):S99-S106, 1997.